Page 1

REGENERON® Regeneron and Sanofi Expand Global Alliance with Multiple Next - Generation , Long - Acting Immunology Antibodies October 1 , 2026 at 1:00 AM EDT REGN20423 , a clinical - stage long - acting IL - 13 monoclonal antibody invented and developed by Regeneron , is added to the alliance , along with a long - acting IL - 4xIL - 13 bispecific and two other long - acting preclinical antibodies from Regeneron Regeneron to receive $ 1 billion upfront with potential for up to an additional $ 7 billion in future milestone payments ; companies to equally share development and commercialization costs , as well as any future profits Regeneron and Sanofi to host a conference call for investors and analysts today at 8:00 am ET / 2 : 00 pm CET TARRYTOWN , N.Y. and PARIS , Oct. 01 , 2026 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals , Inc. ( NASDAQ : REGN ) and Sanofi today announced an expansion of their long - standing antibody collaboration , adding multiple next - generation , long - acting antibodies to the alliance that has jointly established DupixentⓇ ( dupilumab ) as the world - leading treatment for diseases driven by type 2 inflammation . The agreement builds on the companies ' more than 20 - year collaboration , through which more than 1.5 million people are currently receiving Dupixent across nine indications , making it one of the most widely used antibody medicines in the world . " The Regeneron - Sanofi alliance has been one of the most productive in biopharma history . This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster , " said Leonard S. Schleifer , M.D. , Ph.D. , Board co - Chair , President and Chief Executive Officer of Regeneron . " By expanding our alliance , we are positioning promising new long - acting antibodies for the kind of rapid , global impact that our shared work on Dupixent has already achieved . " Under the expanded license and collaboration agreement , the companies will co - develop and co - commercialize four new long - acting , Regeneron - invented antibodies targeting interleukin - 13 ( IL - 13 ) , IL - 4xIL - 13 bispecific , interleukin - 4 ( IL - 4 ) and interleukin - 4 receptor alpha ( IL - 4Ra ) . IL - 13 antibody REGN20423 is currently in a Phase 1 clinical trial for atopic dermatitis , and the other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have the option to include in the collaboration Sanofi's lunsekimig , an investigational bispecific Nanobody Ⓡ VHH therapy targeting TSLP and IL - 13 , exercisable upon completion of its Phase 3 trials for chronic obstructive pulmonary disease . " This is a deliberate first step in igniting Sanofi's innovation engine . Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses , " said Belén Garijo , Chief Executive Officer of Sanofi . " By deepening our collaboration , we will make rapid progress in creating the next generation of meaningful therapies for patients with immune - mediated diseases , while contributing to Sanofi's long - term future . " Under the terms of the agreement , Regeneron will receive an upfront payment of $ 1 billion from Sanofi , with the potential for development , regulatory and commercial milestone payments of up to an additional $ 7 billion . The companies will share development and commercialization costs for the new programs and will split future profits from these potential products 50:50 on a global basis . Regeneron will lead research and development activities , and Sanofi will lead global commercial efforts . The existing profit - sharing agreement regarding Dupixent will not change . " The companies ' clinical and commercial alliance dates to 2003 and has resulted in multiple approved medicines to date , including Dupixent which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease , with over 1.5 million active patients worldwide , " said George D. Yancopoulos , M.D. , Ph.D. , Board co - Chair , President and Chief Scientific Officer at Regeneron , and a principal inventor of Dupixent . " By combining Regeneron's world - class scientific discovery and antibody development expertise with Sanofi's global capabilities and reach , we hope to once again deliver the next wave of innovation in immunology . " The companies have settled their prior collaboration - related litigation . Conference call for investors and analysts Regeneron and Sanofi will host a conference call for investors and analysts today at 8:00 am ET / 2 : 00 pm CET . A presentation will be available for download from the Investor Relations section of regeneron.com and sanofi.com when the conference call starts . Participants may access today's conference call live via webcast on the ' Investors and Media ' page of Regeneron's website at https://investor.regeneron.com/events-and-presentations and on the ' Upcoming Events ' page of Sanofi's website at https://www.sanofi.com/en/investors/news-events/upcoming-events . To participate via telephone , please register in advance at